Rennova Health, Inc. · OTC:RNVA
Rennova Health — CollabRx — IPO Roadshow (June 2014)
24 slides from Rennova Health's IPO roadshow presentation, Jun 18, 2014
Slide 1: CollabRx: Empowering Cancer Care
NASDAQ: CLRX CollabRx: Empowering Cancer Care Expert systems for genomics - based cancer treatment planning Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration No. 333 - 193019 June 17, 2014
Slide 2: Safe Harbor
© 2014 CollabRx, Inc. 2 Safe Harbor When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward - look
Slide 3: Free Writing Prospectus Statement
© 2014 CollabRx, Inc. 3 Free Writing Prospectus Statement CollabRx , Inc. has filed a registration statement on Form S - 3 (Registration No. 333 - 193019) with the Securities and Exchange Commission (the “SEC”) for the offering to which this communication relates. A copy of the preliminary prospectu
Slide 4: Overview of CollabRx
Overview of CollabRx • A clinical decision - support company for precision oncology • Not a lab – provide evidence - based content and expert decision support in SaaS - based and advertising supported business models – Focus on data interpretation, reporting and downstream analytics for clinical dec
Slide 5: Cancer
© 2014 CollabRx, Inc. 5 Cancer • Addressable US market ~ 12 million patients • 1.5 million new US patients in 2013* – Growing to almost 3 million new US patients each year by 2050** • Each day thousands of patients progress beyond “ guidelines” and are candidates for genomic medicine • The U.S. canc
Slide 6: Problem of rapidly changing science and standards in Oncology
Problem of rapidly changing science and standards in Oncology © 2014 CollabRx, Inc. 6 Community Oncology Groups Constant revision of guidelines New clinical evidence for off - label use 1000’s of Clinical Trials Dozens of interacting molecular pathways 100’s of investigatio nal drugs “ Our patients
Slide 7: Emergence of Next Generation Sequencing has created a new market opportunity
© 2014 CollabRx, Inc. 7 Emergence of Next Generation Sequencing (NGS ) has created a new market opportunity * Source: McKinsey • NGS allows analysis of multiple genes at one time ( “ panels”) – Pre - NGS tests were designed to target and capture only one or a few of the most common, well - known gen
Slide 8: How we do it
© 2014 CollabRx, Inc. 8 Editorial Boards & Guidelines Knowledge Base of Treatment Models In - House Knowledge Experts How we do it 8 Representative Sources of Guidelines Representative Available Data Sources:
Slide 9: Over 75 expert advisors from leading institutions
9 Melanoma Melanoma Lung Breast Breast Colorectal Sarcoma Leukemia Prostate Pancreas Pan Cancer Breast Over 75 expert advisors from leading institutions provide best practice insights R epresentative institutional affiliations: © 2014 CollabRx, Inc.
Slide 10: Architecture Overview
Testing and QA Project management Support Build/ deploy policies Content updates Hosting Availability Documentatio n Approval automation Change management Software Engineering Scalable software platform for automated processing and control Knowledge Sources Master Knowledge Base NCI Thesaurus KB (SI
Slide 11: Two product lines derived from the same expert-vetted knowledge base
© 2014 CollabRx, Inc. 11 Two product lines derived from the same expert - vetted knowledge base • TherapyFinder™(TF) Web - based and CancerRx™mobile applications for oncology professionals – Current TFs for melanoma , colorectal , lung and breast c ancers – TFs for prostate cancer, leukemia , lympho
Slide 12: Therapy Finders - interactive and easy to use apps
12 Therapy Finders - interactive and easy to use apps – for physicians and patients © 2014 CollabRx , Inc.
Slide 13: Successful launch of CancerRx at ASCO
13 Successful launch of CancerRx™ at ASCO © 2014 CollabRx, Inc. • 4,390 Total Downloads from 5/28 – 6/3 • 3,424 during ASCO • 1,321 Activations • #2 in i P ad Store under Medical Apps • 5 Star Rating to date Existing MPT Users New Registrants Share of Registrants – New and Existing MPT Users
Slide 14: GVA supplies authoritative, automated and scalable reporting
GVA supplies authoritative, automated and scalable reporting on test results via API or portal © 2014 CollabRx, Inc. 14
Slide 15: Focus on specific aspects of the clinical genetic testing workflow
Specimen Handling • Acquisition • Transport • Lab Acceptance Sample Prep • Extract DNA from biopsy tissues • Results in material suitable for analysis with NGS platforms Genetic Analysis • NGS sequencing • Results in files that contain raw sequence data as direct export from NGS platforms Bioinforma
Slide 16: Actionability framework
© 2014 CollabRx, Inc. 16 Rationale for actionability (Strength of evidence) Basis of actionability Guidelines Actionability framework provides insight to clinical approaches “beyond” Guidelines
Slide 17: Partnerships, strategic alliances, customers and sponsors
17 Partnerships, strategic alliances, customers and sponsors © 2014 CollabRx, Inc. 17 Academic Institutions Cancer Centers Professional Organizations University of Chicago Ohio State University Jackson Laboratory Stanford Hospitals OncoSolutions Cancer Center (Singapore) American Society of Clinical
Slide 18: Multiple revenue sources and potentials
18 © 2014 CollabRx, Inc. 18 Multiple revenue sources and potentials Web and Mobile Apps Pharma Everyday Health/MPT Pharma Physicians and patients Pharma Sponsorships License fees Ad revenue Customization (Fee for service) Subscription Per - test fees (Software - as - a - Service) D ata analytics GVA
Slide 19: Seasoned Leadership team
© 2014 CollabRx, Inc. 19 Seasoned Leadership team Thomas Mika, MBA; Chairman, President, and CEO – Tegal, IMTEC, Cresap, National Science Foundation, HBS George Lundberg, MD; Chief Medical Officer and Editor - in - Chief – AMA, WebMD, Medscape, Stanford (Professor, pathology), Lundberg Institute Cli
Slide 20: Board of Directors
© 2014 CollabRx, Inc. 20 Board of Directors Paul R. Billings, MD, PhD – Author, lecturer, consultant, professor and thought leader in genomic medicine. CMO, Thermo Fisher Scientific , Member of FDA Science Board, VA Genomic Medicine Advisory Committee, IOM Genomic Medicine Roundtable; LabCorp , Trov
Slide 21: Balance Sheet as of 3/31/14
21 © 2014 CollabRx, Inc. 21 CollabRx, Inc ., Balance Sheet as of 3/31/14 Cash $1,430 Other current $871 Total current assets $2,301 Total assets $4,315 Current liabilities $368 Promisory note $509 Deferred tax liability $500 Total liabilites $1,390 Stockholders equity $2,925 Liabilities and equity $
Slide 22: Capitalization as of 3/31/14
22 © 2014 CollabRx, Inc. 22 CollabRx, Inc . Capitalization as of 3/ 31/ 14 Issued and Outstanding Preferred - Common 2,005,187 Total Shares Outstanding 2,005,187 Unissued Warrants (non price-protected) 92,888 Options and RSUs 820,397 Remaining in Equity Plans 148,428 Total Unissued 1,061,713 Fully D
Slide 23: Approaching milestones to monitor CollabRx achievement
23 © 2014 CollabRx, Inc. 23 Approaching milestones to monitor CollabRx achievement What it indicates Additional lab customers Gaining market share Additional Therapy Finder apps Increasing scope of cancer coverage and additional revenue opportunities Launch of CancerRx mobile app Major milestone: be
Slide 24: www.collabrx.com
www.collabrx.com